The trial showed that KT-110 has superior efficacy in reducing alcohol consumption. KT-110 will be deliverable in a once-daily tablet (proprietary formulation). KT-110’s mode of action is novel to Alcohol Use Disorder (AUD) and works by simultaneously modulating the noradrenergic and serotonergic brain receptors that counteract the neurobiological processes involved in addictionAlcohol dependence, or AUD, is a serious public health issue and the medical need for the treatment of alcoholism is considerable and unmet. Kinnov Therapeutics expects to have clear guidance from the FDA in early 2024 on the phase III trial
07 November, 2023
Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of breast cancer.
07 November, 2023
Investors need confidence and predictability if they are to invest in the fight against antibiotic resistance, finds a new report.
02 November, 2023